Impact of the COVID-19 pandemic on reported cancer diagnoses in Bavaria, Germany DOI Creative Commons
Sven Voigtländer,

Amir Hakimhashemi,

Nina Grundmann

и другие.

Journal of Cancer Research and Clinical Oncology, Год журнала: 2023, Номер 149(10), С. 7493 - 7503

Опубликована: Март 24, 2023

Abstract Purpose The aim of our study was to explore the impact COVID-19 pandemic on reported cancer cases in Bavaria, Germany, by comparing pre-pandemic (March 2019 February 2020) and period 2020 2021). Methods Data incident were retrieved from Bavarian Cancer Registry (until 22nd April 2022). We included patients with malignant situ neoplasms pathology departments consistent reporting. calculated number during 95% confidence intervals (CI) Bonferroni correction (α = 0.0018) based a Poisson approach. stratified for malignancy (malignant, situ), tumor site, month year. Results available 30 out 58 (51.7%) Bavaria. Incident dropped 42,857 39,980 (− 6.7%; CI − 8.7%, 4.7%). Reductions higher colon, rectum, skin/melanoma as well liver (> 10.0% reduction) less breast (4.9% reduction). No case reductions observed pancreas, esophagus, ovary, cervix. Percent changes largest 20.9%; 24.7%, 16.8%) January 2021 25.2%; 28.8%, 21.5%) compared previous Declines tended be larger neoplasms. Conclusion Detection diagnosis substantially reduced pandemic. Potential effects, e.g. stage shift tumors or an increase mortality, need monitored.

Язык: Английский

Seroconversion rates following COVID-19 vaccination among patients with cancer DOI Creative Commons
Astha Thakkar, Jesus D. Gonzalez‐Lugo, Niyati Goradia

и другие.

Cancer Cell, Год журнала: 2021, Номер 39(8), С. 1081 - 1090.e2

Опубликована: Июнь 5, 2021

Язык: Английский

Процитировано

341

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium DOI Creative Commons
Petros Grivas, Ali Raza Khaki, Trisha M. Wise‐Draper

и другие.

Annals of Oncology, Год журнала: 2021, Номер 32(6), С. 787 - 800

Опубликована: Март 20, 2021

Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort patients and 2019 (COVID-19) reported to the COVID-19 Cancer Consortium (CCC19) identify prognostic clinical factors, including laboratory measurements anticancer therapies. active or historical laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March 18 November 2020 were included. The primary outcome was severity measured on an ordinal scale (uncomplicated, hospitalized, admitted intensive care unit, mechanically ventilated, died within 30 days). Multivariable regression models included demographics, status, therapy timing, COVID-19-directed therapies, (among hospitalized patients). A total 4966 (median age 66 years, 51% female, 50% non-Hispanic white); 2872 (58%) 695 (14%) died; 61% had that present, diagnosed, treated year prior diagnosis. Older age, male sex, obesity, cardiovascular pulmonary comorbidities, renal disease, diabetes mellitus, black race, Hispanic ethnicity, worse Eastern Cooperative Oncology Group performance recent cytotoxic chemotherapy, hematologic malignancy associated higher severity. Among patients, low absolute lymphocyte count; neutrophil platelet abnormal creatinine; troponin; lactate dehydrogenase; C-reactive protein diagnosed early in pandemic (January-April 2020) than those later. Specific therapies (e.g. R-CHOP, platinum combined etoposide, DNA methyltransferase inhibitors) 30-day all-cause mortality. Clinical factors older hematological malignancy, chemotherapy) poor among COVID-19. Although further studies are needed, caution required utilizing particular NCT04354701.

Язык: Английский

Процитировано

299

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer DOI Creative Commons
Alfredo Addeo, Pankil Shah, Natacha Bordry

и другие.

Cancer Cell, Год журнала: 2021, Номер 39(8), С. 1091 - 1098.e2

Опубликована: Июнь 18, 2021

Язык: Английский

Процитировано

227

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer DOI Creative Commons
Sidse Ehmsen, Anders Asmussen, Stefan Starup Jeppesen

и другие.

Cancer Cell, Год журнала: 2021, Номер 39(8), С. 1034 - 1036

Опубликована: Июль 27, 2021

Язык: Английский

Процитировано

147

NETosis and Neutrophil Extracellular Traps in COVID-19: Immunothrombosis and Beyond DOI Creative Commons
Yuanfeng Zhu, Xiaoli Chen, Xin Liu

и другие.

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Март 2, 2022

Infection with SARS-CoV-2, the causative agent of Coronavirus disease 2019 (COVID-19) pandemic, causes respiratory problems and multifaceted organ dysfunction. A crucial mechanism COVID-19 immunopathy is recruitment activation neutrophils at infection site, which also predicts severity poor outcomes. The release neutrophil extracellular traps (NETs), occurring during a regulated form cell death known as NETosis, key effector function that mediates harmful effects caused by neutrophils. Abundant NETosis NET generation have been observed in many patients, leading to unfavorable coagulopathy immunothrombosis. Moreover, excessive are now more widely recognized mediators additional pathophysiological abnormalities following SARS-CoV-2 infection. In this minireview, we introduce subtypes NET-producing (e.g., low-density granulocytes) explain biological importance NETs protein cargos COVID-19. addition, discuss mechanisms upregulating viral processes entry replication) well host pro-NET proinflammatory mediator release, platelet activation, autoantibody production). Furthermore, provide an update main findings immunothrombosis other COVID-19-related disorders, such aberrant immunity, neurological post syndromes including lung fibrosis, disorder, tumor progression, deteriorated chronic illness. Finally, address potential prospective treatment strategies target dysregulated formation via inhibition promotion degradation, respectively.

Язык: Английский

Процитировано

138

Severity of COVID-19 in patients with lung cancer: evidence and challenges DOI Creative Commons
Antonio Passaro, Christine M. Bestvina,

Maria Velez Velez

и другие.

Journal for ImmunoTherapy of Cancer, Год журнала: 2021, Номер 9(3), С. e002266 - e002266

Опубликована: Март 1, 2021

Cancer patients are highly vulnerable to SARS-CoV-2 infections due frequent contacts with the healthcare system, immunocompromised state from cancer or its therapies, supportive medications such as steroids and most importantly their advanced age comorbidities. Patients lung have consistently been reported suffer an increased risk of death compared other cancers. This is possibly combination specific pathophysiological aspects, including underlying pulmonary compromise smoking history pressures on respiratory services caused by related pandemic. Rationally safely treating during pandemic has become a continuous challenge over last year. Deciding whether offer, modify, postpone even cancel treatments for this particular patient’s population crucial recurrent dilemma professionals. Chemotherapy, immunotherapy targeted agents represent distinct risks factors in context COVID-19 that should be balanced short-term long-term consequences delaying care. Despite rapid persistent trend pandemic, declared WHO March 11, 2020, still ongoing at time writing (January 2021), various efforts were made oncologists worldwide understand impact cancer. Adapted recommendations our evidence-based practice guidelines developed all stakeholders. Different small large-scale registries, Consortium (CCC19) Thoracic Cancers International Collaboration quickly collected data, supporting care decisions under challenging circumstance created Several guidance prioritizing aspects order mitigate adverse effects crisis, potentially reducing morbidity mortality These helped inform about treatment established disease, continuation clinical research screening. In review, we summarize available evidence regarding direct indirect patients.

Язык: Английский

Процитировано

125

Global, regional, and national burden of esophageal cancer: a systematic analysis of the Global Burden of Disease Study 2021 DOI Creative Commons

Weiqiu Jin,

Kaichen Huang,

Zeyu Ding

и другие.

Biomarker Research, Год журнала: 2025, Номер 13(1)

Опубликована: Янв. 6, 2025

Abstract Background and objective Esophageal cancer (EC) is the seventh most prevalent globally sixth leading cause of cancer-related mortality. This study aimed to provide an updated stratified assessment rates in EC incidence, mortality, disability-adjusted life-years (DALYs) from 1990 2021 by sex, age, Socio-demographic Index (SDI) at global, regional, national levels, as well project future trends both regionally. Methods Data about age-standardized (ASRs) incidence (ASIR), mortality (ASDR), probability death (ASPoD) DALYs (ASDALYRs) were obtained Global Burden Disease (GBD) study. Estimated annual percentage changes (EAPCs) average (AAPC) calculated over certain periods describe temporal burdens. The analyses disaggregated sexes, GBD super-regions regions, nations/territories, age-groups, SDI quintiles. A Bayesian age-period-cohort (BAPC) model was constructed global regional ASRs 2022–2035. Results Despite reductions ASRs, with ASIR, ASDR, ASDALYR 6.65 [5.88, 7.45] (95% uncertainty interval), 6.25 [5.53, 7.00], 148.56 [131.71, 166.82], decreasing 24.9%, 30.7%, 36.9% 1990–2021, respectively, absolute burden numbers increased 2021, probably because population growth aging. newly diagnosed cases, deaths, 576,529 [509,492, 645,648], 356,263 [319,363, 390,154], 12,999,265 [11,522,861, 14,605,268] 62.53%, 51.18%, 33.28% compared records 1990. geographical pattern consistent: locations highest predominantly located Asian Cancer Belt African Corridor, East Asia, Southern Sub-Saharan Africa, Eastern Africa regions heaviest burdens, Malawi, Eswatini, Mongolia, Zambia, Zimbabwe 2021. However, owing size, China, India, United States, Japan, Brazil had More pronounced alleviations observed high indicated their lower AAPC values those low-SDI locations, while increasing especially Chad (114.76% for example), Sao Tome Principe (97.93%), Togo (92.53%), Northern Mariana Islands (84.32%), Liberia (82.33%), etc. Smoking remained contributor across significantly heavier males, males being 2.89 2.88 times higher, than females. Across all age groups, posed increasingly significant threat men aged > 75 years. From 2022 2035, ASR projections show only modest decrease are expected increase nearly super-regions. Conclusion remains significant, disparities regions. Region-specific age-targeted measures crucial addressing these inequalities, light burdens older Efforts should be taken finding more solid attributions risk factors better identify high-risk populations inform targeted prevention screening, ultimately reduce efficient cost-effective way. Graphical

Язык: Английский

Процитировано

5

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies DOI Creative Commons
Lee M. Greenberger, Larry A. Saltzman, Jonathon W. Senefeld

и другие.

Cancer Cell, Год журнала: 2021, Номер 39(10), С. 1297 - 1299

Опубликована: Сен. 7, 2021

Язык: Английский

Процитировано

96

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer DOI Open Access
Sonali M. Smith, KERRI WACHTER, Howard A. Burris

и другие.

Journal of Clinical Oncology, Год журнала: 2021, Номер 39(10), С. 1165 - 1184

Опубликована: Фев. 2, 2021

First Page

Язык: Английский

Процитировано

73

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma DOI Creative Commons
Adolfo Aleman,

Bhaskar Upadhyaya,

Kevin Tuballes

и другие.

Cancer Cell, Год журнала: 2021, Номер 39(11), С. 1442 - 1444

Опубликована: Окт. 20, 2021

Язык: Английский

Процитировано

73